India's drug regulator approves study on mixing of Covaxin, Covishield

India's drug regulator has given approval for a study on mixing of Covid-19 vaccines Covaxin and Covishield, official sources said

Visitors wait to get their dose of Covid-19 vaccine at an inoculation centre in Bikaner, Sunday, Aug. 8, 2021. (PTI Photo)
Visitors wait to get their dose of Covid-19 vaccine at an inoculation centre in Bikaner, Sunday, Aug. 8, 2021. (PTI Photo)
Press Trust of India New Delhi
1 min read Last Updated : Aug 11 2021 | 11:05 AM IST

India's drug regulator has given approval for a study to be conducted by the Christian Medical College (CMC), Vellore on mixing of COVID-19 vaccines Covaxin and Covishield, official sources said on Wednesday.

An expert panel of the Central Drugs Standard Control Organisation (CDSCO) on July 29 had recommended granting permission for conducting the study.

The trial will involve 300 healthy volunteers.

"The aim of the study is to assess the feasibility on whether a person can be given two different vaccine shots -- one each of Covishield and Covaxin -- to complete the inoculation course," a source said.

Separately, a recent study by the Indian Council of Medical Research (ICMR) involving 98 people, 18 of whom had inadvertently received Covishield as the first dose and Covaxin as the second in Uttar Pradesh, showed that combining these two COVID-19 vaccines elicited better immunogenicity than two doses of the same vaccine.

The study also found that immunisation with combination of Covishield and Covaxin was safe and the adverse effects were also found to be similar when compared to the same dose regimen.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusDelta variant of coronavirusCoronavirus VaccineCoronavirus Tests

First Published: Aug 11 2021 | 11:05 AM IST

Next Story